Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.

Jouve, Jean-Louis

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma. [electronic resource] - Journal of hepatology 09 2019 - 516-522 p. digital

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1600-0641

10.1016/j.jhep.2019.04.021 doi


Adult
Aged
Aged, 80 and over
Antineoplastic Agents--adverse effects
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Carcinoma, Hepatocellular--drug therapy
Diarrhea--chemically induced
Female
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Liver Neoplasms--drug therapy
Male
Middle Aged
Pravastatin--adverse effects
Prognosis
Progression-Free Survival
Quality of Life
Sorafenib--adverse effects